Despite climbing quarterly profits of 5 per cent, diabetic drug manufacturer Takeda has left its outlook unchanged due to uncertainty over their blockbuster drug Actos.
The company posted first quarter results at the same time as another Japanese drug maker, Daiichi Sankyo.
Actos is the major earner for Takeda, and as Glaxo drug Avandia has been put through the media mill, sales of actos have in fact climbed. In June, sales of Actos climbed by 40 per cent.
Takeda have held their forecast due to upcoming deliberations over the safety of Avandia and Actos.

Get our free newsletters

Stay up to date with the latest news, research and breakthroughs.

You May Also Like

Conversation about doctors’ appointments occurring virtually rumbles on

More than half of GP appointments are still being delivered remotely in…

Public Health England considers low carb approach for type 2 diabetes

The low carb approach is being considered by the government to be…

Top diabetes professor drafts risk assessment document for frontline COVID-19 staff

The health and wellbeing of frontline NHS staff has been prioritised among…